Overview

Aprepitant for Postoperative Nausea and Vomiting in Laparoscopic Hysterectomy

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
0
Participant gender:
Female
Summary
- Gynecological surgery is associated with a high incidence of postoperative nausea and vomiting. - NK1 receptor antagonists such as aprepitant appear to be highly effective for treating acute and delayed emesis, and yet understanding of the efficacy of different doses of aprepitant is limited. - We performed a prospective, randomized, double-blinded placebo-controlled study of 123 female adults scheduled for laparoscopic hysterectomy who received 80 mg aprepitant, 125 mg aprepitant, or a placebo.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Gachon University Gil Medical Center
Collaborators:
Asan Medical Center
University of California, San Francisco
Treatments:
Aprepitant
Fosaprepitant
Criteria
Inclusion Criteria:

- female laparoscopic hysterectomy isoflurane anesthesia postoperative opioid use

Exclusion Criteria:

- liver disease neurologic disease active pulmonary disease cardiac arrhythmia allergies
to any perioperative medications